Sanofi reported mixed Phase 3 results for its glucosylceramide synthase (GCS) inhibitor venglustat: the drug met primary endpoints in a Phase 3 trial for Gaucher disease but failed a separate late‑stage study in Fabry disease. The company confirmed the Gaucher success in its program update while acknowledging the Fabry setback in parallel communications. The dual outcomes underscore modality‑specific biology across lysosomal disorders and leave Sanofi evaluating regulatory paths and development priorities for venglustat. Analysts and company commentary flagged the data divergence as a critical determinant for next regulatory and commercial moves.